[A21-77] Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 19.11.2021
Project no.:
A21-77
Commission:
Commission awarded on 31.05.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)
Hint of non-quantifiable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A14-48 | Enzalutamide (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A13-33 | Enzalutamide - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A18-80 | Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-46 | Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
| A21-132 | Enzalutamide (prostate cancer) - Addendum to Commission A21-77 | Commission completed |
Federal Joint Committee (G-BA)
2021-11-19 A G-BA decision was published.